Search details
1.
Cetuximab every 2 weeks versus standard weekly dosing administration schedule.
Future Oncol
; 20(7): 393-407, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37850363
2.
Chemotherapy postimmunotherapy for recurrent metastatic head and neck squamous cell carcinoma.
Curr Opin Oncol
; 35(3): 166-177, 2023 05 01.
Article
in English
| MEDLINE | ID: mdl-36966495
3.
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Oncologist
; 27(2): e194-e198, 2022 03 04.
Article
in English
| MEDLINE | ID: mdl-35641218
4.
Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?
Curr Opin Oncol
; 34(3): 196-203, 2022 05 01.
Article
in English
| MEDLINE | ID: mdl-35671120
5.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 22(4): 463-475, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33684370
6.
Systemic treatment of metastatic squamous cell carcinoma of the head and neck: proposal for management changes.
Curr Opin Oncol
; 33(3): 160-167, 2021 05 01.
Article
in English
| MEDLINE | ID: mdl-33782359
7.
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Invest New Drugs
; 39(6): 1641-1648, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34322775
8.
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Cancer
; 125(18): 3208-3218, 2019 09 15.
Article
in English
| MEDLINE | ID: mdl-31246283
9.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
N Engl J Med
; 375(19): 1856-1867, 2016 11 10.
Article
in English
| MEDLINE | ID: mdl-27718784
10.
Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
Curr Opin Oncol
; 31(3): 146-151, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30893146
11.
Molecular genetics of head and neck squamous cell carcinoma.
Curr Opin Oncol
; 31(3): 131-137, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30893149
12.
Treatment of inoperable elderly head and neck cancer patients.
Curr Opin Oncol
; 31(3): 152-159, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30985496
13.
Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: The CIRCUTEC Prospective Study.
Clin Chem
; 65(10): 1267-1275, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31387885
14.
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Br J Clin Pharmacol
; 85(6): 1357-1366, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30811063
15.
Approach to the Patient with Recurrent/Metastatic Disease.
Curr Treat Options Oncol
; 20(8): 65, 2019 06 25.
Article
in English
| MEDLINE | ID: mdl-31240480
16.
Evaluation of the information given to patients undergoing total pharyngolaryngectomy and quality of life: a prospective multicentric study.
Eur Arch Otorhinolaryngol
; 276(9): 2531-2539, 2019 Sep.
Article
in English
| MEDLINE | ID: mdl-31240456
17.
CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Oncologist
; 23(9): 1079-1082, 2018 09.
Article
in English
| MEDLINE | ID: mdl-29866947
18.
Natural History of Localized and Locally Advanced Atypical Lung Carcinoids after Complete Resection: A Joined French-Italian Retrospective Multicenter Study.
Neuroendocrinology
; 106(3): 264-273, 2018.
Article
in English
| MEDLINE | ID: mdl-28813709
19.
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Lancet Oncol
; 18(8): 1104-1115, 2017 08.
Article
in English
| MEDLINE | ID: mdl-28651929
20.
Editorial: Head and neck squamous cell cancer: ways to optimize the treatment and improve the outcomes.
Curr Opin Oncol
; 34(3): 169, 2022 05 01.
Article
in English
| MEDLINE | ID: mdl-35671119